July 29, 2024
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform
AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice
AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment
Dexcom Stock Plummets 40% After Disappointing CGM Sales and Weak Guidance
Dexcom, CGM, Sales Challenges, Stock Drop, Weak Guidance
FDA Approves New Oral Alzheimer’s Therapy, Expands Label for Grifols SCIg Therapy
FDA, Alzheimer’s disease, Grifols, XEMBIFY, immunoglobulin, subcutaneous, immunodeficiency, plasma-derived therapeutics
Cognition Therapeutics’ Stock Plummets Following Disappointing Phase 2 Alzheimer’s Trial Results
Cognition Therapeutics, Alzheimer’s disease, Phase 2 trial, stock decline, CT1812, oral treatment, efficacy endpoint
NewAmsterdam Achieves Success in First of Three Pivotal Cardio Studies
NewAmsterdam, pivotal studies, cardio class, pharmaceuticals, medical breakthrough
FDA Places Clinical Hold on vTv Therapeutics’ Diabetes Drug Program
vTv Therapeutics, diabetes drug, clinical hold, FDA, cadisegliatin, type 1 diabetes
Anavex’s New Analysis of Alzheimer’s Pill Shows Mixed Results
Anavex, Alzheimer’s disease, blarcamesine, Phase IIb/III trial, clinical efficacy, neurodegeneration, cognitive decline, amyloid-beta, brain atrophy, EMA approval.
Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage
Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225
FDA Halts vTv Therapeutics’ Type-1 Diabetes Clinical Trial Due to Chromatographic Signal
vTv Therapeutics, FDA, clinical trial, type-1 diabetes, cadisegliatin, chromatographic signal, patient safety, glucokinase activator